NCT04604678

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

Pilot Study Into the Use of Metformin and Low Dose Naltrexone (LDN) for Patients With Coronavirus Disease 2019 (COVID-19) - Assessment of Short and Long Term Effects

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: AgelessRx · Industry
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.

Detailed description

The researchers will treat 40 patients with metformin (1500 mg/day) and LDN (4.5 mg/day) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19. These 40 patients will be compared with 40 control patients who will receive regular care. All patients will be asked to complete surveys at baseline and after 1, 2, and 4 weeks after initiation of treatment. The difference with baseline at each time point will be assessed. The surveys will assess COVID-19 symptoms severity.

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Metformin	Metformin at 1500 mg/day
DRUG	Naltrexone	Naltrexone at 4.5 mg/day (LDN)

Timeline

• Start date: 2021-02-01
• Primary completion: 2021-08-01
• Completion: 2021-10-01
• First posted: 2020-10-27
• Last updated: 2022-10-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study